Price
$26.61+5.51%Social Signal Score
Analyst Ratings
15 analystsRevenue
$582.78M-33.71%Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Damien McDonald
- Sector
- Healthcare
- Industry
- Medical - Devices
- Employees
- 7,802
- Beta
- 1.43
- Country
- US
- Piotroski score
- 5 / 9 (Middling)
- Altman Z-score
- -0.36
Financials
Revenue
$582.78M-33.7%Net Income
$-1.19M-104.3%EBITDA
$86.60M-5.7%Free Cash Flow
$31.14M+6.4%EPS (diluted)
$-0.02-102.9%Shares Outstanding (diluted)
57.60M+40.4%Operating Expenses
$295.42MCash & Debt
$12.56MReturn of Capital
$530.0KRevenue by Segment (annual)
$3.85BQuote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $2.25B | $-1.18B | $-20.86 |
| 2024 | $2.11B | $-825.49M | $-14.93 |
| 2023 | $1.71B | $-33.26M | $-0.61 |
| 2022 | $1.56B | $-13.29M | $-0.28 |
| 2021 | $1.43B | $71.66M | $-2.02 |
| 2020 | $1.12B | $42.63M | $1.13 |
| 2019 | $3.33B | $-527.65M | $-11.66 |
| 2018 | $3.67B | $140.20M | $3.50 |
| 2017 | $3.30B | $151.09M | $3.69 |
| 2016 | $3.65B | $128.11M | $3.12 |
| 2015 | $3.97B | $167.74M | $4.05 |
| 2014 | $4.62B | $392.10M | $9.18 |
| 2013 | $4.21B | $178.63M | $4.68 |
| 2012 | $3.91B | $-64.40M | $-2.13 |
Valuation
ENOVhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
50+0.00%Social Signal Score
Mentions (11)
- Newsprnewswire.com·13d ago·Neutral
Enovis becomes first multi-registry industry sponsor of AAOS Registry Program Company expands its support from the American Joint Replacement Registry to include the Shoulder & Elbow Registry ROSEMONT, Ill., Sept. 22, 2026 /PRNewswire/ -- The American Academy of Orthopaedic Surgeons (AAOS) announced that Enovis ™ has expanded its support of the AAOS Registry Program, becoming the first industry partner to sponsor multiple AAOS registries.
View source ↗ - Newszacks.com·32d ago·Positive
What Makes Enovis (ENOV) a New Buy Stock Enovis (ENOV) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
View source ↗ - Newszacks.com·32d ago·Neutral
Enovis (ENOV) Loses 33% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner Enovis (ENOV) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.
View source ↗ - Newszacks.com·33d ago·Neutral
Enovis Boosts Surgical Robotics Portfolio With eCential Acquisition ENOV is set to acquire eCential Robotics to expand into orthopedic surgical robotics, though the deal is expected to pressure 2027 margins.
View source ↗ - Newsseekingalpha.com·34d ago·Positive
Enovis Corporation (ENOV) M&A Call Transcript Enovis Corporation (ENOV) M&A Call Transcript
View source ↗ - Newsmarketbeat.com·35d ago·Neutral
Enovis Targets Robotic Surgery Expansion With €155M eCential Robotics Deal Enovis NYSE: ENOV said it has entered a binding offer to acquire eCential Robotics, a developer of surgical robotics technology, in a move the orthopedic company said will expand its enabling-technology capabilities and accelerate its pathway into robotic surgery.
View source ↗ - Newsprnewswire.com·35d ago·Neutral
eCential Robotics Announces Binding Offer from Enovis eCential Robotics platform to join Enovis' enabling technology portfolio. GRENOBLE, France and FRANKLIN, Tenn.
View source ↗ - Newsglobenewswire.com·35d ago·Negative
…ire eCential Robotics, a Leading Developer of Enabling Technologies and Surgical Robotics Dallas, TX, Sept. 01, 2026 (GLOBE NEWSWIRE) -- – Enovis™ Corporation (NYSE: ENOV), an innovation-driven medical technology company, announced today that it has entered into a binding offer to acquire eCential Robotics, a leading developer of enabling technologies and surgical robotics. The acquisition expands the ASTRA™ enabling technology platform with robotic automation capabilities, creating a more compr…
View source ↗ - Newsglobenewswire.com·35d ago·Neutral
Enovis to Participate in the 2026 Wells Fargo Healthcare Conference Dallas, TX, Aug. 31, 2026 (GLOBE NEWSWIRE) -- Enovis™ Corporation (NYSE: ENOV), an innovation-driven, medical technology growth company, today announced that it will participate in the 2026 Wells Fargo HealthCare conference on Tuesday, September 8, 2026 at the Encore Boston Harbor.
View source ↗ - Newsseekingalpha.com·45d ago·Neutral
…nt, wearable augmented reality device for orthopedic surgery, targets the fast-growing ambulatory surgery center market and recently achieved full commercialization. ENOV's fundamentals are weak—slim margins, high leverage, and thin free cash flow—but these are already priced in, while Arvis's growth potential is not.
View source ↗ - Newsmarketbeat.com·59d ago·Neutral
Enovis Q2 Earnings Call Highlights Enovis NYSE: ENOV reported second-quarter 2026 sales of $583 million, up 3% on a reported basis and 5% organically, as growth in its Reconstruction business offset a slower but still expanding Performance & Recovery segment. Management said the company's results reflected improved commercial execution, new-product adoption and operational productivity, while also noting pressure from Middle East-related disruptions and higher inflation.
View source ↗
Earnings
Thu, Nov 5(in 4 weeks)
Consensus estimate $0.76 per share
Typical surprise +8.5% (median, so one quarter with a near-zero estimate can't distort it)
- Thu, Aug 6$0.90 vs $0.85beat
- Thu, May 7$0.89 vs $0.82beat
- Thu, Feb 26$0.95 vs $0.81beat
- Thu, Nov 6$0.75 vs $0.67beat
- Thu, Aug 7$0.79 vs $0.74beat
- Thu, May 8$0.81 vs $0.74beat
Estimates and results for ENOV via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by ENOV officers and directors.
- Bought
- $1.4m
- Sold
- $45k
22 trades
4 trades
- Engert Oliverbought
- Mcdonald Damienbought
- Engert Oliverbought
- Engert Oliverbought
- Engert Oliverbought
- Engert Oliverbought
- Engert Oliverbought
- Engert Oliverbought
74 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
No disclosed congressional trades in ENOV.
Self-reported filings, amounts as brackets. Via Senate/House disclosures.